



November 14, 2018

The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir,

Subject: Outcome of Board Meeting.

This has reference to our letter dated 03rd November, 2018.

At the meeting of the Board of Directors of the company held on 14th November 2018 the following decisions were taken:

- 1) It was decided to hold the 28th Annual General Meeting on Thursday the 20th December 2018.
- 2) The Register of Members and Share Transfer Books of the Company will remain closed from Tuesday the 18th December 2018 to Thursday the 20th December, 2018 (both days inclusive).
- 3) We are enclosing here to the unaudited quarterly results for the quarter ended 30th September 2018.

This is for your information and records.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED

DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Encls : as above

TRANSGENE BIOTEK LIMITED
68, 69 & 70, Anrich Industrial Area, Bollaram, MEDAK DISTRICT.

Statement of Un - Audited Standalone Financial Results for the Quarter/Half Year ended 30th September, 2018

(Amount in Rs.)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Audited)	30.09.2018 (Unaudited)	30.09.2017 (Audited)	31.03.2018 (Audited)
INCOME						
Revenue from operations	-	712,870	-	712,870	-	1,182,406
Other income (net)	438,470	438,470	438,470	876,940	930,940	73,726,947
Total income	438,470	1,151,340	438,470	1,589,810	930,940	74,909,353
EXPENSES						
Employee benefits expense	621,147	460,811	1,043,936	1,081,958	1,844,194	3,276,852
Cost of materials consumed	19,166	(1,476)	36,939	17,690	36,939	347,382
Changes in inventories of finished goods and work-in-progress	-	-	-	-	-	139,715
Finance costs	1,252,748	-	7,497,593	1,252,748	8,189,343	10,281,689
Depreciation and amortisation expense	24,734,110	24,723,250	24,736,799	49,457,360	49,473,598	98,914,413
Other operating expenses	548,230	849,056	864,163	1,397,286	1,413,989	18,471,754
Total expenses	27,175,401	26,031,641	34,179,430	53,207,042	60,958,063	131,431,805
Profit before exceptional items, share of profit from associate & joint venture and tax	(26,736,931)	(24,880,301)	(33,740,960)	(51,617,232)	(60,027,123)	(56,522,452)
Exceptional item (net)						
Profit before share of profit from associate & joint venture and tax	(26,736,931)	(24,880,301)	(33,740,960)	(51,617,232)	(60,027,123)	(56,522,452)
Share of profit of associate	-	-	-	-	-	-
Share of profit of joint venture	-	-	-	-	-	-
Profit before tax	(26,736,931)	(24,880,301)	(33,740,960)	(51,617,232)	(60,027,123)	(56,522,452)
Tax expense						
Prior Period Taxes	-	-	-	-	-	7,860,849
Current tax	-	-	-	-	-	-
Deferred tax	-	-	-	-	-	-
Total tax expense	-	-	-	-	-	7,860,849
Profit for the year	(26,736,931)	(24,880,301)	(33,740,960)	(51,617,232)	(60,027,123)	(64,383,301)
Other comprehensive income						
A Items that will not be reclassified subsequently to profit or loss						
(a) Remeasurements cost of post employment benefits	353	262	5,926	615	10,469	1,860
Total other comprehensive income	353	262	5,926	615	10,469	1,860
Total comprehensive income for the year	(26,736,578)	(24,880,039)	(33,735,034)	(51,616,617)	(60,016,654)	(64,381,441)
Profit for the year attributable to:						
- Owners of the Company	(26,736,578)	(24,880,039)	(33,735,034)	(51,616,617)	(60,016,654)	(64,381,441)
- Non controlling interests	-	-	-	-	-	-
	(26,736,578)	(24,880,039)	(33,735,034)	(51,616,617)	(60,016,654)	(64,381,441)
Other comprehensive income for the year attributable to:						
- Owners of the Company	-	-	-	-	-	-
- Non controlling interests	-	-	-	-	-	-
	-	-	-	-	-	-
Total comprehensive income for the year attributable to:						
- Owners of the Company	(26,736,578)	(24,880,039)	(33,735,034)	(51,616,617)	(60,016,654)	(64,381,441)
	(26,736,578)	(24,880,039)	(33,735,034)	(51,616,617)	(60,016,654)	(64,381,441)
Earnings per equity share						
(Equity shares, par value of Rs. 10 each)						
Basic (Rs.)	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000
Diluted (Rs.)	(0.35)	(0.33)	(0.45)	(0.68)	(0.79)	(0.85)
	(0.35)	(0.33)	(0.45)	(0.68)	(0.79)	(0.85)

For Transgene Biotek Limited



Dr. K. Koteswara Rao
Managing Director

14.11.2018
Hyderabad

TRANSGENE BIOTEK LIMITED
68, 69 & 70, Anrich Industrial Area, Bollaram, MEDAK DISTRICT.

Statement of Un - Audited Standalone Balance Sheet as at 30th September, 2018
In accordance with the accounting standard 34 "Interim Financial Reporting" (Ind AS 34)
(Amount in Rs.)

Particulars	As at 30.09.2018 (Un - Audited)	As at 31.03.2018 (Audited)
A. ASSETS		
I. Non-current assets		
Property, plant and equipment	25,428,156	26,384,340
Other intangible assets	435,102,223	483,305,399
Intangible assets under development	18,676,633	18,676,633
Financial assets		
(b) Loans	230,204,250	230,204,250
Other non-current assets	-	194,256
Total Non - Current Assets	709,411,262	758,764,878
II. Current Assets		
Inventories	-	420,911
Financial assets		
(a) Cash and cash equivalents	521,445	1,019,326
Other current assets	6,571,050	6,407,654
Total Current assets	7,092,495	7,847,891
Total Assets (A)	716,503,757	766,612,769
B. EQUITY AND LIABILITIES		
I. Equity		
Equity share capital	757,700,000	757,700,000
Other equity	(457,963,391)	(409,180,999)
Equity attributable to owners of the Company	299,736,609	348,519,001
Total Equity	299,736,609	348,519,001
II. Non-current liabilities		
Financial Liabilities		
(a) Borrowings	36,866,464	38,448,556
Provisions	230,204,250	230,204,250
Other non-current liabilities	11,400,223	12,277,163
Total Non-current liabilities	278,470,937	280,929,969
III. Current liabilities		
Financial liabilities		
(a) Borrowings	62,432,274	60,044,784
(b) Trade payables	5,883,324	5,492,891
Provisions	69,579,401	69,909,891
Other current liabilities	401,212	1,716,233
Total Current liabilities	138,296,211	137,163,799
Total Equity and liabilities (B)	716,503,757	766,612,769

NOTES TO THE ACCOUNTS – Q2 2018-19

- Next set of studies on oral delivery of vaccines with defined critical objectives are progressing and on completion, formal pre-clinical studies shall be taken up on both oral vaccines and oral Insulin.
- Series of acclaimed patents from Britain, Germany, France & Italy have been granted on oral delivery technology.
- No. of Investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th November 2018.
- The Company is operating in only one segment of Bulk Drugs, hence Segment Wise Report is not applicable as per IND AS 108.
- These results have been prepared in accordance with the Ind AS notified under the companies (Indian Accounting Standards) Rules 2015, as amended.

For Transgene Biotek Limited



Dr. K. Koteswara Rao
Managing Director


14.11.2018
Hyderabad



Limited Review Report

To
The Board of Directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of M/s. TRANSGENE BIOTEK LIMITED ("the Company") for the quarter ended September 30, 2018 and year to date from April 1, 2018 to September 30, 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ("the Circular").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and the Circular, is the responsibility of the company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan our review to obtain moderate assurance as to whether the statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. We did not review the interim financial results and other financial information in respect of the wholly owned subsidiary company viz. Transgene Biotek HK Limited (1,69,52,001 shares of US \$ 1 each), the operations of which were not carried for the period under review as explained by the management.




6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results for the quarter ended September 30, 2018 and year to date from April 1, 2018 to September 30, 2018 prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and disclosure requirement) regulations, 2015, read with the Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lakshmi & Associates
Chartered Accountants
FR No. 012482S

N. Lakshmi

N. Lakshmi
Partner
M.No. 223790



Place: Hyderabad
Date: 14/11/2018